투자판단관련주요경영사항(임상시험결과) (대사이상지방간염 (MASH) 치료제 DD01의 미국 임상 제2상 임상시험결과보고서(CSR) 수령)[코]
디앤디파마텍· 347850 More filings
Received: 8/21/2026 · Reporter: 디앤디파마텍
디앤디파마텍은 대사이상지방간염(MASH) 치료제 DD01의 미국 임상 제2상 임상시험결과보고서(CSR)를 받았습니다.
🏢 Past 12 months filing pattern (this company)
- Total filings
- 35 filings
- Same category
- 15 filings
- Previous same-category filing
- 7/14/2026(38 days ago)
- Corrections / withdrawals
- 1 filing
Filing source / License
The original PDF/HTML of this filing is provided by FSS DART. MarketBubbles displays only metadata (title, receipt number, type, reporter) and a rule-based summary; we do not mirror the original PDF body (per FSS ToS).